Dr. Benedetto Farsaci, MD - Bristol-Myers Squibb - Principal Scientist - Oncology Biomarkers

Dr. Benedetto Farsaci

MD

Bristol-Myers Squibb

Principal Scientist - Oncology Biomarkers

Princeton, New Jersey | United States

Main Specialties: Allergy & Immunology

Additional Specialties: Cancer Immunology and Immunotherapy


Top Author

Dr. Benedetto Farsaci, MD - Bristol-Myers Squibb - Principal Scientist - Oncology Biomarkers

Dr. Benedetto Farsaci

MD

Introduction

Primary Affiliation: Bristol-Myers Squibb - Princeton, New Jersey , United States

Specialties:

Additional Specialties:


View Dr. Benedetto Farsaci’s Resume / CV

Education

Sep 2007
University of Catania, Italy
MD Specialization in Clinical Biomchemistry
Clinical Biochemistry, Clinical Molecular Biology, and Laboratory Medicine
Jun 2002
University of Catania, Italy
MD

Experience

Feb 2017
Principal Scientist, Oncology Biomarkers
Translational Medicine Lead, Hematology
Bristol-Myers Squibb, Princeton, NJ
Dec 2014
Research Fellow
Head, Molecular Immunology Group
Laboratory of Tumor Immunology and Biology, NCI, NIH, Bethesda, MD
Jun 2011
Visiting Fellow
Post Doctoral Fellow, Recombinant Vaccine Group
Laboratory of Tumor Immunology and Biology, NCI, NIH, Bethesda, MD
May 2007
MD Residence in Hematology and Bone Marrow Transplant
Resident Physician
Ferrarotto Hospital, Catania, Italy

Publications

17Publications

448Reads

1535Profile Views

408PubMed Central Citations

Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.

Cancer Immunol Res 2016 09 2;4(9):755-65. Epub 2016 Aug 2.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138028PMC
September 2016
46 Reads
4 Citations

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.

J Immunother Cancer 2015 17;3:52. Epub 2015 Nov 17.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Center Drive, Room 8B13 MSC 1750, Bethesda, MD 20892 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0096-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647578PMC
November 2015
16 Reads
4 Citations

Therapeutic cancer vaccines.

Adv Cancer Res 2014 ;121:67-124

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-800249-0.00002-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324585PMC
April 2015
24 Reads
11 Citations
5.321 Impact Factor

Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Cancer Immunol Res 2014 Nov 4;2(11):1090-102. Epub 2014 Aug 4.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221465PMC
November 2014
37 Reads
16 Citations

Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.

Int J Cancer 2014 Aug 22;135(4):862-70. Epub 2014 Feb 22.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467468PMC
August 2014
13 Reads
5.085 Impact Factor

Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy.

J Immunol 2014 Mar 10;192(6):2622-33. Epub 2014 Feb 10.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1301369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122292PMC
March 2014
27 Reads
7 Citations
4.922 Impact Factor

Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Cancer Immunol Res 2014 Feb 4;2(2):133-41. Epub 2013 Nov 4.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, 13N208, MSC-1750, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-13-0108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004961PMC
February 2014
14 Reads
37 Citations

Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Clin Cancer Res 2013 Nov 18;19(22):6205-18. Epub 2013 Sep 18.

Authors' Affiliations: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; Medivation Inc., San Francisco, California; and GlobeImmune Inc., Louisville, Colorado.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833876PMC
November 2013
21 Reads
25 Citations
8.722 Impact Factor

Effects of conventional therapeutic interventions on the number and function of regulatory T cells.

Oncoimmunology 2013 Oct;2(10):e27025

Interinstitutional Multidisciplinary Biobank (BioBIM); Department of Laboratory Medicine and Advanced Biotechnologies; IRCCS San Raffaele Pisana; Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.27025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862634PMC
October 2013
20 Reads
20 Citations
6.283 Impact Factor

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

Int J Cancer 2013 Aug 16;133(3):624-36. Epub 2013 Mar 16.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663913PMC
August 2013
25 Reads
52 Citations
5.085 Impact Factor

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Semin Oncol 2012 Jun;39(3):323-39

Recombinant Vaccine Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2012.02.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356994PMC
June 2012
18 Reads
44 Citations
3.900 Impact Factor

Distinct effects of saracatinib on memory CD8+ T cell differentiation.

J Immunol 2012 May 26;188(9):4323-33. Epub 2012 Mar 26.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1101439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378668PMC
May 2012
12 Reads
4 Citations
4.922 Impact Factor

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.

Int J Cancer 2012 Apr 8;130(8):1948-59. Epub 2011 Aug 8.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MA 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.26219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232304PMC
April 2012
14 Reads
43 Citations
5.085 Impact Factor

Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.

Int J Cancer 2010 Oct;127(7):1603-13

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.25177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924188PMC
October 2010
20 Reads
17 Citations
5.085 Impact Factor

TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression.

Cancer Immunol Immunother 2009 Nov 25;58(11):1809-18. Epub 2009 Mar 25.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 8B09, MSC 1750, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-009-0692-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499107PMC
November 2009
25 Reads
11 Citations
3.941 Impact Factor